Document |
Document Title |
WO/2024/083120A1 |
Disclosed in the present invention are a benzylaminoquinoline compound and a preparation method therefor. The present invention specifically relates to a compound represented by formula (II), a stereoisomer thereof and a pharmaceutically...
|
WO/2024/084447A2 |
Compounds of formula (I) and an enantiomer, a diastereomer, a racemate, a tautomer, a prodrug, a hydrate, a solvate and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3 and W, are as defined in the specification, are usef...
|
WO/2024/085224A1 |
The present invention provides: a type 1 crystal of 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-5-((trifluor
omethyl)sulfonyl)benzo[d]oxazole represented by formula (1) and having diffraction peaks at 2θ of 14.3 ± 0.2°, 15.6 ± 0....
|
WO/2024/085695A1 |
The present invention relates to a novel altiratinib derivative, a manufacturing method therefor, and a composition comprising same as an active ingredient for the prevention, alleviation, or treatment of skin pigmentation. The altiratin...
|
WO/2024/085225A1 |
The present invention provides: a type 1 crystal of 2-(5-cyclopropyl-3-(ethylsulfonyl)pyridin-2-yl)-5-((trifluor
omethyl)sulfinyl)benzo[d]oxazole represented by formula (1) and having diffraction peaks at 2θ of 8.5 ± 0.2°, 12.0 ± 0.2...
|
WO/2024/086296A1 |
The present disclosure relates to the field of medicinal chemistry. In particular, the disclosure relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein Ring A,...
|
WO/2024/084360A1 |
The present invention relates to compounds of Formula A, and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such proce...
|
WO/2024/083177A1 |
The present invention relates to an aromatic acetylene derivative, a preparation method therefor, and a medical use of a pharmaceutical composition containing the derivative. Specifically, the present invention relates to an aromatic ace...
|
WO/2024/083208A1 |
Provided in the present invention are a compound having a structure as represented by general formula (I); a deuterated substance, a stereoisomer or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing same...
|
WO/2024/084186A1 |
The presentation invention relates to compounds of formula (I) and pharmaceutical compositions thereof. The compounds may be used to treat an infection, such as a parasitic infection or a bacterial infection. In some embodiments, the com...
|
WO/2024/083237A1 |
The disclosure provides substituted heteroaryl bicyclic compounds as represented in Formula I and the use thereof, wherein, A1, A2, B1, B2, B3, ring Z, L, Cy1 and Cy2 are defined herein. The compounds of Formula I can be used to prevent ...
|
WO/2024/082470A1 |
Provided are an alprostadil coupled nitric oxide donor compound or a pharmaceutically acceptable salt thereof. The medicine is decomposed into two active ingredients, namely alprostadil and nitric oxide, in vivo, the pharmacological acti...
|
WO/2024/083933A1 |
There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I), (I) and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are modulator...
|
WO/2024/083886A1 |
The present invention relates to novel RNA-binding azetidine compounds of general formula (I) and stereoisomeric forms, hydrates, solvates and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing s...
|
WO/2024/080655A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...
|
WO/2024/081893A1 |
The present disclosure relates generally to various salt forms and compositions thereof useful for the modulation of interleukin-1 receptor-associated kinase 4 ("IRAK4") via ubiquitination and/or degradation and uses of the same in the t...
|
WO/2024/079682A1 |
The present invention relates to a sulfoximine compound having a novel structure, stereoisomers thereof or pharmaceutically acceptable salts thereof, and a use thereof for preventing or treating histone deacetylase-mediated diseases The ...
|
WO/2024/078569A1 |
The present invention relates to an aromatic amide derivative, a preparation method therefor, and a use of a pharmaceutical composition comprising same in medicine. Specifically, the present invention relates to an aromatic amide derivat...
|
WO/2024/081904A1 |
This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
|
WO/2024/081927A1 |
Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
|
WO/2024/078513A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of a disorder, pharmaceutical compositions and methods of making and using the same.
|
WO/2024/076670A2 |
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
|
WO/2024/076891A1 |
Disclosed herein are compounds of Formula (IV), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (IV...
|
WO/2024/076672A1 |
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
|
WO/2024/074611A1 |
The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
|
WO/2024/077057A1 |
Compounds having activity as kinase inhibitors are provided. The compounds have Structure (I), or a stereoisomer, tautomer, or salt thereof, wherein, R1, R3, and m are as defined herein. Methods associated with preparation and use of suc...
|
WO/2024/075815A1 |
The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...
|
WO/2024/075051A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD an...
|
WO/2024/076731A1 |
The present invention provides compositions and methods for treating hidradenitis suppurativa (HS) or an apocrine gland infection. In one embodiment, the invention provides a method for treating HS or an apocrine gland infection in a sub...
|
WO/2024/074414A1 |
The present invention relates to compounds of Formula (I), (I) or an agronomically acceptable salt of said compounds wherein Q, R2, R3 and U are as defined herein. The invention further relates to herbicidal compositions which comprise a...
|
WO/2024/068950A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
WO/2024/067773A1 |
Provided herein are compounds and methods for modulating or inhibiting TEAD. Further provided herein are pharmaceutical compositions comprising the TEAD inhibitors and methods of treatment using the TEAD inhibitors or the pharmaceutical ...
|
WO/2024/071439A1 |
The present invention provides a novel compound that has an STAT6 inhibitory effect and is efficacious in treating inflammatory diseases and allergic diseases such as atopic dermatitis. A compound represented by general formula (I) and h...
|
WO/2024/067818A1 |
The present disclosure relates to a chimeric compound used for targeted degradation of a BCL-2 protein, a preparation method therefor, and pharmaceutical application thereof. Specifically, the present disclosure relates to a heterocyclic...
|
WO/2024/068520A1 |
The present invention relates to 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
|
WO/2024/067445A1 |
Provided are a compound of formula (I) having inhibitory activity for protein arginine methyltransferase 5, and a method for synthesis and use of the compound.
|
WO/2024/067812A1 |
The present invention relates to an aromatic acetylene derivative, a preparation method therefor, and a medical use of a pharmaceutical composition containing said derivative. Specifically, the present invention relates to an aromatic ac...
|
WO/2024/066128A1 |
The present invention provides an isoxazoline substituted benzamide compound, and a stereoisomer and an agriculturally or veterinarily acceptable salt thereof. The compound is as shown in formula (I): wherein X represents hydrogen, halog...
|
WO/2024/067660A1 |
The present disclosure relates to an aza-fused ring compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to an aza-fused ring compound represented by general formula (I), a ...
|
WO/2024/073587A1 |
Compounds and methods for inhibiting Nrf2 by activating KEAP1.
|
WO/2024/069634A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of cancer in a subject in need thereof are also provided.
|
WO/2024/068519A1 |
The present invention relates to 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
WO/2024/067304A1 |
The present invention provides a compound with inhibitory activity against Sigma2 and 5HT2A. The compound can be used as a dual-target inhibitor of Sigma2 and 5HT2A for the treatment of a related disease mediated by Sigma2 receptor activ...
|
WO/2024/073426A1 |
Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
|
WO/2024/068517A1 |
The present invention relates to 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
|
WO/2024/073502A1 |
The present disclosure relates to novel compounds that inhibit glucose-induced degradation-deficient (GID) E3 ligase, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related ...
|
WO/2024/067813A1 |
The present invention relates to an aromatic acetylene derivative, a preparation method therefor, and pharmaceutical use of a pharmaceutical composition comprising the derivative. Specifically, the present invention relates to an aromati...
|
WO/2024/067744A1 |
The present invention relates to heterocyclic substituted quinazoline, a preparation method therefor, and use thereof. Specifically, the compound of the present invention has a structure represented by formula (IA), formula (IB) or formu...
|
WO/2024/073576A1 |
Provided herein are compounds of Formula (I) which are inhibitors of furin, pharmaceutical compositions containing them, processes for their preparation, and their use in therapy (e.g., for the treatment of respiratory syncytial virus).
|